| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-04-29 | GLPG1972 | osteoarthritis | preclinical | Galapagos (Belgium) | |
| 2017-04-28 | eptinezumab - ALD403 | chronic migraine | 2b | Alder Biopharmaceuticals (USA - WA) | CNS diseases - Neurological diseases |
| 2017-04-27 | SD-809 - deutetrabenazine | tardive dyskinesia | 3 | Teva Pharmaceutical Industries (Israel) | Neurological diseases - CNS diseases |
| 2017-04-27 | AZ8838, AZ3451 | Heptares Therapeutics (UK), a wholly-owned subsidiary of Sosei Group (Japan) AstraZeneca (UK) | |||
| 2017-04-27 | QR-110 | Leber’s congenital amaurosis type 10 | 1-2 | ProQR Therapeutics (The Netherlands) | Rare diseases - Genetic diseases - Ophtalmological diseases |
| 2017-04-27 | MRG-201 | pathological fibrosis | 1 | Miragen Therapeutics (USA - Co) | Fibrotic diseases |
| 2017-04-26 | inclisiran (ALN-PCSsc) | atherosclerotic cardiovascular disease (ASCVD, familial hypercholesterolemia (FH), | 3 | Alnylam Therapeutics (USA - MA) The Medicines Company (USA - NJ) | Cardiovascular diseases |
| 2017-04-25 | filgotinib and GS-9876 | cutaneous lupus erythematosus | 2 | Galapagos (Belgium) | Autoimmune diseases – Inflammatory diseases - Dermatological diseases |
| 2017-04-24 | belinostat (Beleodaq®) | relapsed or refractory peripheral T-cell lymphoma | Clinigen (UK) Onxeo (France) | Cancer - Oncology | |
| 2017-04-24 | abemaciclib (LY2835219) | hormone receptor-positive, HER2-negative locoregionally recurrent or metastatic breast cancer | 3 | Eli Lilly (USA - IN) | Cancer - Oncology |
| 2017-04-24 | Resolaris® - ATYR1940 | limb girdle muscular dystrophy (LGMD) | 1-2 | Atyr Pharma (USA - CA) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2017-04-24 | Resolaris® | facioscapulohumeral muscular dystrophy | 1b-2 | Atyr Pharma (USA - CA) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2017-04-22 | JNJ-4178 (AL-335, odalasvir (ACH-3102) and simeprevir= | chronic hepatitis C | 2 | Alios Biopharma, a J&J company (USA - NJ) Achillion Pharmaceuticals (USA - CT) | Infectious diseases |
| 2017-04-22 | A4250 | primary biliary cirrhosis, cholestatic pruritus | 2 | Albireo (Sweden) | Autoimmune diseases - Hepatic diseases - Liver diseases |
| 2017-04-22 | MK-3682B (uprifosbuvir/grazoprevir/rusazvir) | hepatitis C | 2 | Merck&Co (USA - NJ) | Infectious diseases |
| 2017-04-22 | BMS-986036 (Pegylated FGF21) | NASH (non-alcoholic steatohepatitis) | 2 | BMS (USA - NY) | Hepatic diseases - Liver diseases |
| 2017-04-21 | BGB-290 and BGB-A317 | advanced solid tumors | 1b | BeiGene (China) | Cancer - Oncology |
| 2017-04-21 | GS-0976 ( NDI-010976) | NASH (non-alcoholic steatohepatitis) | Gilead Sciences (USA - CA) | Hepatic diseases - Liver diseases | |
| 2017-04-20 | CA4P and everolimus | neuroendocrine tumors | 1 | Mateon Therapeutics (USA - CA) | Cancer - Oncology |
| 2017-04-20 | IMP321 and pembrolizumab | melanoma | 1 | Prima Biomed (Australia) | Cancer - Oncology |
